248 related articles for article (PubMed ID: 17679700)
21. Faster publication isn't always better.
Fuster V; Farkouh ME
Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
[No Abstract] [Full Text] [Related]
22. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
Nissen SE; Wolski K
Arch Intern Med; 2010 Jul; 170(14):1191-1201. PubMed ID: 20656674
[TBL] [Abstract][Full Text] [Related]
23. Analytical issues regarding rosiglitazone meta-analysis.
Claggett B; Wei LJ
Arch Intern Med; 2011 Jan; 171(2):179-80; author reply 180. PubMed ID: 21263111
[No Abstract] [Full Text] [Related]
24. The rosiglitazone meta-analysis.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
[No Abstract] [Full Text] [Related]
25. [Rosiglitazone: no increase in cardiovascular mortality].
Jazet IM; Meinders AE
Ned Tijdschr Geneeskd; 2009; 153():A942. PubMed ID: 19930745
[TBL] [Abstract][Full Text] [Related]
26. [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
Erdmann E; Scherbaum WA
MMW Fortschr Med; 2007 Dec; 149(49-50):49-50. PubMed ID: 18236983
[No Abstract] [Full Text] [Related]
27. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
[No Abstract] [Full Text] [Related]
28. Rosiglitazone and cardiovascular disease: a diabetologist's perspective.
Grant PJ
Diab Vasc Dis Res; 2007 Jun; 4(2):75-6. PubMed ID: 17654437
[No Abstract] [Full Text] [Related]
29. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Hiatt WR; Kaul S; Smith RJ
N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
[No Abstract] [Full Text] [Related]
30. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
[TBL] [Abstract][Full Text] [Related]
31. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
32. Rosiglitazone--continued uncertainty about safety.
Drazen JM; Morrissey S; Curfman GD
N Engl J Med; 2007 Jul; 357(1):63-4. PubMed ID: 17551160
[No Abstract] [Full Text] [Related]
33. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
[TBL] [Abstract][Full Text] [Related]
34. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
Odom J; Williamson B; Carter L
Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
[No Abstract] [Full Text] [Related]
35. The Avandia debacle: methodology and practical importance of the findings.
Meneghini LF; Florez H; Tamariz L
South Med J; 2007 Nov; 100(11):1062-3. PubMed ID: 17984727
[No Abstract] [Full Text] [Related]
36. Meta-analysis of incidence of rare events.
Lane PW
Stat Methods Med Res; 2013 Apr; 22(2):117-32. PubMed ID: 22218366
[TBL] [Abstract][Full Text] [Related]
37. The cardiovascular safety of rosiglitazone.
Ajjan RA; Grant PJ
Expert Opin Drug Saf; 2008 Jul; 7(4):367-76. PubMed ID: 18613801
[TBL] [Abstract][Full Text] [Related]
38. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.
Juurlink DN; Gomes T; Lipscombe LL; Austin PC; Hux JE; Mamdani MM
BMJ; 2009 Aug; 339():b2942. PubMed ID: 19690342
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
40. Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.
Monami M; Marchionni N; Mannucci E
Diabetes Res Clin Pract; 2008 Oct; 82(1):48-57. PubMed ID: 18775581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
